Named executive officer

Jeff Mann

Senior Vice President, General Counsel and Product Development·Embecta Corp.

About

Jeff Mann serves as Senior Vice President, General Counsel and Product Development, prior to which he served as the Senior Vice President, General Counsel and Head of Corporate Development of Diabetes Care at BD until the Separation. Previously, Jeff served as General Counsel and Corporate Secretary of Cantel Medical Corp. Prior to Cantel, Jeff spent 14 years with Boston Scientific Corporation in roles including M&A, venture capital investments, SEC and corporate governance, patent strategy, litigation, and business unit support for the Med Surg group.

Age 53

Also at Embecta Corp.

CA Carrie L. Anderson Director RH Robert (Bob) J. Hombach Director DK Devdatt (Dev) Kurdikar President and Chief Executive Officer, Embecta Corp. MP Milton M. Morris, Ph.D. Director CM Claire Pomeroy, M.D. Director (Lead Director effective as of the 2026 Annual Meeting) KP Karen N. Prange Director

Past roles

No prior roles disclosed
The proxy statement discloses no roles beyond this person's current position. Disclosure is required only for the most recent five years.

Fixed compensation

Data from FY 2025
Salary
$600,769
Component Annual base salary
All other compensation
$34,017
Total compensation
$3,005,372

Performance compensation

Data from FY 2025

Cash incentive

Annual cash incentive
$470,554
Form Cash
Evaluation period FY2025

Stock awards

Stock awards
$1,900,032
Form TVUs and PSUs

Related

Source: Embecta Corp. proxy statement (SEC Schedule 14A)

Where the filing does not disclose a value, this page states "Not disclosed" rather than estimating. Smaller filers are exempt from disclosing metric targets and achievement, and larger filers may omit forward targets for competitive reasons.

See how VectorShift works for your firm

Request Demo